Boris Itkin

Dr. Boris Itkin

University of Buenos Aires
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BIBoris Itkin
Boris Itkin
AGAgustin Garcia
Agustin Garcia
SSSamanta Straminsky
Samanta Straminsky
EAEduardo Daniel Adelchanow
Eduardo Daniel Adelchanow
MPMatias Pereyra
Matias Pereyra
ABAriel Bardach
Ariel Bardach
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2= 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2= 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2= 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2= 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.

Verified
Journal Article
Open access
PDF file
BIBoris Itkin
Boris Itkin
ABAlastair Breen
Alastair Breen
LTLyudmila Turyanska
Lyudmila Turyanska
ESEduardo Omar Sandes
Eduardo Omar Sandes
TBTracey Bradshaw
Tracey Bradshaw
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez
Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.

5 May 2018 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
BIBoris Itkin
Boris Itkin
SSSamanta Straminsky
Samanta Straminsky
GRGabriela De Ronato
Gabriela De Ronato
DLDaniel Lewi
Daniel Lewi
AMAdolfo Marantz
Adolfo Marantz
Ariel BardachAriel Bardach
Ariel Bardach
Data on long-term prognosis of metastatic GCT (mGCT) is scant. The frequency of spontaneous regressions (SRs) is unknown. We aimed to estimate the prognosis of mGCT. We searched electronic scientific literature databases and generic Internet from January 1980 to August 2017. After identifying eligible studies we performed descriptive analyses and meta-analyses to estimate overall survival (OS), disease specific survival (DSS) and frequency of SRs in the years before the widespread use of denosumab. We performed pre-specified subgroup analyses of studies published before and after 2000 and of those with more and less than 10 years of follow-up. After retrieving and combining data from 26 relevant retrospective case-series totaling 242 patients with a median follow-up of 6.9 years, the estimated pooled OS was 86.9% (95% CI 78.0-94.2). Pooled DSS was 88.0% (95% CI 79.7-94.7). SRs were observed in 4.5% of patients. In the subgroup of studies published after 2000 mGCT was the only cause of death of affected subjects. In case-series with a follow-up longer than 10 years pooled DSS was 69.7% (95% CI 25.5-99.8). To our knowledge this is the first study to derive estimated pooled OS and DSS of mGCT based on a large dataset. SRs were not exceptional phenomena. In a long run the disease could impact in a significant way on the life expectancy of affected subjects.

15 June 2024 in IJID Regions
Verified
Journal Article
Open access
BABASSEM Ibrahim AWADA
BASSEM Ibrahim AWADA
AZAref Zribi
Aref Zribi
AGAhmad Ghoche
Ahmad Ghoche
HAHasan Al-Sayegh
Hasan Al-Sayegh
MMManyando Milupi
Manyando Milupi
JAJorge Abarca
Jorge Abarca
Candida species frequently cause bloodstream infections; however, there is a lack of epidemiological studies on candidemia in Oman. To address this, we conducted a retrospective study at Sultan Qaboos Comprehensive Cancer and Research Center from October 2021 to October 2023. Our study identified 27 episodes of candidemia among 26 patients with cancer, with an incidence of 4.9 per 1000 admissions. Non-albicans Candida (NAC) prevailed over C. albicans (70.37% vs 29.62%), with C. glabrata as the predominant NAC species (n = 10; 37%). The 30-day mortality rate was 40.7%, showing no significant difference between NAC and C. albicans but was notably higher in critically ill patients (P = 0.03). In Oman, NAC surpasses C. albicans as a causative pathogen for candidemia with a high mortality rate.

1 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
BIBoris Itkin
Boris Itkin
AGAgustin Garcia
Agustin Garcia
SSSamanta Straminsky
Samanta Straminsky
EAEduardo Daniel Adelchanow
Eduardo Daniel Adelchanow
MPMatias Pereyra
Matias Pereyra
ABAriel Bardach
Ariel Bardach
BackgroundThe reported rates of HER2 positivity in uterine cervical cancer (CC) range from 0–87%. The organization of clinical studies of HER2 targeting agents in CC requires a better knowledge of HER2 positivity prevalence. We aimed to provide precise estimates of HER2 overexpression and amplification in CC.MethodsWe conducted a PRISMA compliant meta-analytic systematic review. We searched electronic databases for articles reporting the proportion of HER2 positivity by immunohistochemistry or in situ hybridization in CC. We performed descriptive analyses of all 65 included studies. Of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators.ResultsThe estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5–11.7%) in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9–34.8%) in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0–5.8%) and 24.9% (CI 95%: 12.6–39.6%), respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates.ConclusionA small proportion of CC is expected to be HER2 positive. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.

18 March 2025 in Medicine International
Verified
Journal Article
Open access
PDF file
BIBoris Itkin
Boris Itkin
PDPrashant Ajit Deshpande
Prashant Ajit Deshpande
APAnoopa Pullanhi
Anoopa Pullanhi
HAHasan Al‑Sayegh
Hasan Al‑Sayegh
DADoaa Abbas
Doaa Abbas
IHIbrahim Al Haddabi
Ibrahim Al Haddabi
Reported next‑generation sequencing (NGS) failure rates vary widely and are primarily based on studies of common tumor types. The present study aimed to estimate NGS failure rates in rare tumors and their association with preanalytical variables and sequencing methods in a single institution. Patients with sarcomas, rare carcinomas, and rare melanomas who underwent NGS between January 2022 and October 2023 were eligible for participation in the present study. NGS was performed as whole exome/transcriptome sequencing (WETS) based on hybrid capture or multigene commercial targeted panel. Clinicopathological and NGS‑related data were extracted from clinical charts. Univariable logistic regression models were constructed with the outcome variable NGS failure and the following explanatory variables: Assay, sampling method, tissue type , and storage time. A total of 102 NGS reports from 86 patients with sarcomas (73.3%), rare carcinomas (16.3%), and melanomas (10.5%) were included. The median age of the patients was 40 years [interquartile range (IQR), 23‑61 years]. Samples were obtained by biopsy (51%) and surgery (48%) and were collected from soft tissue (92.1%) or bone (7.9%) lesions. The median storage time was 2.5 months (IQR, 1.3‑4.6 months). Targeted panel and WETS were used in 39.2 and 60.8% of reports, respectively. NGS failure due to insufficient material quantity or quality was observed in 14.7% of tests, corresponding to 4.7% of patients. Repeated testing was successful in 7 out of 8 patients. WETS was significantly associated with a higher probability of NGS failure due to the insufficient quantity or quality of material compared to targeted panel (odds ratio, 11.4; 95% confidence interval, 1.4‑90.4; P=0.022). In summary, our findings suggest that the NGS failure rates in rare tumors are comparable to the rates reported in prevalent neoplasms. WETS can be associated with more frequent NGS failure than targeted panel. Retesting can often overcome the initial NGS testing failure.